UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.641-655

2016

Volltextzugriff (PDF)

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

Diabetes care, 2008-08, Vol.31 (8), p.1479-1484

2008

Volltextzugriff (PDF)

Editorial: a non‐dietary treatment for coeliac disease—two steps forward, one step back? Authors’ reply

Alimentary pharmacology & therapeutics, 2019-10, Vol.50 (8), p.956-957

2019

Volltextzugriff (PDF)

Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease

Alimentary pharmacology & therapeutics, 2019-09, Vol.50 (5), p.547-555

2019

Volltextzugriff (PDF)

Elevated serum interleukin‐2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease

Alimentary pharmacology & therapeutics, 2019-10, Vol.50 (8), p.901-910

2019

Volltextzugriff (PDF)

A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease

Frontiers in immunology, 2021-05, Vol.12, p.661622-661622

2021

Volltextzugriff (PDF)

Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease

Alimentary pharmacology & therapeutics, 2020-01, Vol.51 (2), p.244-252

2020

Volltextzugriff (PDF)

Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease

BMC medicine, 2020-11, Vol.18 (1), p.362, Article 362

2020

Volltextzugriff (PDF)

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

The lancet. Gastroenterology & hepatology, 2023-05, Vol.8 (5), p.446-457

2023

Volltextzugriff (PDF)

Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients

Journal of neuroimmunology, 2012-05, Vol.246 (1), p.100-107

2012

Volltextzugriff (PDF)

Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1-Phosphate Receptor-1 Modulator

Journal of clinical pharmacology, 2012-07, Vol.52 (7), p.996-1006

2012

Volltextzugriff (PDF)

Safety and Efficacy of Colesevelam HCl in the Treatment of Elderly Patients

Drugs & aging, 2014-06, Vol.31 (6), p.461-470

2014

Volltextzugriff (PDF)

Diabetic Macular Edema: Correlations with Available Diabetes Therapies — Evidence Across a Qualitative Review of Published Literature from MEDLINE and EMBASE

Drug safety, 2010-08, Vol.33 (8), p.643-652

2010

Volltextzugriff (PDF)

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

Archives of internal medicine (1960), 2008-10, Vol.168 (18), p.1975

2008

Volltextzugriff (PDF)

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy

Archives of internal medicine (1960), 2008-07, Vol.168 (14), p.1531

2008

Volltextzugriff (PDF)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1591-1600

2016

Volltextzugriff (PDF)

A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes

Current medical research and opinion, 2010-06, Vol.26 (6), p.1321-1331

2010

Volltextzugriff (PDF)

A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain

Clinical therapeutics, 2007-03, Vol.29 (3), p.399-412

2007

Volltextzugriff (PDF)

Use of an Exposure-Response Model to Aid Early Drug Development of an Oral Sphingosine 1-Phosphate Receptor Modulator

Journal of clinical pharmacology, 2009-01, Vol.49 (1), p.50-62

2009

Volltextzugriff (PDF)

824 – Acute Gluten-Induced Symptoms in Celiac Disease (CED) are Quantitatively Correlated with Serum Cyotkine Response

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-177-S-177

2019

Volltextzugriff (PDF)

821 – A Randomized, Placebo-Controlled Evaluation of the Clinical Tolerability, Pharmacodynamic (PD) & Pharmacokinetic (PK) Profiles of Subcutanteous (SC) Versus Intradermal (ID) Dosing of Nexvax2, a Peptide Treatment for Celiac Disease (CED)

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-175-S-176

2019

Volltextzugriff (PDF)

Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial

Circulation (New York, N.Y.), 2018-10, Vol.138 (18), p.1963-1973

2018

Volltextzugriff (PDF)

Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain

Journal of clinical pharmacology, 2016-01, Vol.56 (1), p.67-77

2016

Volltextzugriff (PDF)

Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin

Journal of clinical pharmacology, 2016-02, Vol.56 (2), p.203-212

2016

Volltextzugriff (PDF)

Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain: Exposure-Response Modeling of Average Daily

Journal of clinical pharmacology, 2016-01, Vol.56 (1), p.67-77

2016

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(39)
Humans
(37)
Male
(20)
Female
(19)
Adult
(17)
Pharmacology & Pharmacy
(15)
Middle Aged
(14)
Biological And Medical Sciences
(11)
Double-Blind Method
(11)
Dose-Response Relationship, Drug
(10)
Medical Sciences
(9)
Aged
(8)
Animals
(8)
Adolescent
(7)
Diabetes Mellitus, Type 2 - Drug Therapy
(7)
Immunology
(7)
Diabetes
(6)
General & Internal Medicine
(6)
Medicine, General & Internal
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

Editorial: a non‐dietary treatment for coeliac disease—two steps forward, one step back? Authors’ reply

Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease

Elevated serum interleukin‐2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease

A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease

Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease

Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients

Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1-Phosphate Receptor-1 Modulator

Safety and Efficacy of Colesevelam HCl in the Treatment of Elderly Patients

Diabetic Macular Edema: Correlations with Available Diabetes Therapies — Evidence Across a Qualitative Review of Published Literature from MEDLINE and EMBASE

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes

A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain

Use of an Exposure-Response Model to Aid Early Drug Development of an Oral Sphingosine 1-Phosphate Receptor Modulator

824 – Acute Gluten-Induced Symptoms in Celiac Disease (CED) are Quantitatively Correlated with Serum Cyotkine Response

821 – A Randomized, Placebo-Controlled Evaluation of the Clinical Tolerability, Pharmacodynamic (PD) & Pharmacokinetic (PK) Profiles of Subcutanteous (SC) Versus Intradermal (ID) Dosing of Nexvax2, a Peptide Treatment for Celiac Disease (CED)

Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial

Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain

Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin

Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain: Exposure-Response Modeling of Average Daily

Suchergebnisse filtern